Zobrazeno 1 - 5
of 5
pro vyhledávání: '"Julia K. Harms"'
Autor:
Tet Woo Lee, Dean C. Singleton, Julia K. Harms, Man Lu, Sarah P. McManaway, Amy Lai, Moana Tercel, Frederik B. Pruijn, Andrew M. J. Macann, Francis W. Hunter, William R. Wilson, Stephen M. F. Jamieson
Publikováno v:
Molecular Oncology, Vol 18, Iss 8, Pp 1885-1903 (2024)
Tumour hypoxia promotes poor patient outcomes, with particularly strong evidence for head and neck squamous cell carcinoma (HNSCC). To effectively target hypoxia, therapies require selection biomarkers and preclinical models that can accurately model
Externí odkaz:
https://doaj.org/article/8463ca23a4994262a7d8bf8b809ac374
Autor:
Tet Woo Lee, Amy Lai, Julia K. Harms, Dean C. Singleton, Benjamin D. Dickson, Andrew M. J. Macann, Michael P. Hay, Stephen M. F. Jamieson
Publikováno v:
Cancers, Vol 12, Iss 12, p 3743 (2020)
Patient survival from head and neck squamous cell carcinoma (HNSCC), the seventh most common cause of cancer, has not markedly improved in recent years despite the approval of targeted therapies and immunotherapy agents. Precision medicine approaches
Externí odkaz:
https://doaj.org/article/62fe96a8f22d4dcb8ee2bf095ead9ddb
Autor:
Julia K. Harms, Tet-Woo Lee, Tao Wang, Amy Lai, Dennis Kee, John M. Chaplin, Nick P. McIvor, Francis W. Hunter, Andrew M. J. Macann, William R. Wilson, Stephen M.F. Jamieson
Publikováno v:
Cells, Vol 8, Iss 7, p 717 (2019)
Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activated prodru
Externí odkaz:
https://doaj.org/article/dd7ebfffd5a142ad8a67293e0040e022
Autor:
Kyle Tamshen, Heather D. Maynard, Yue Wang, Martin Middleditch, Stephen M. F. Jamieson, Ries J. Langley, Julia K. Harms, Jo K. Perry
Publikováno v:
Biomacromolecules. 22(2)
Growth hormone (GH) has been implicated in cancer progression andis a potential target for anticancer therapy. Currently, pegvisomant is the only GH receptor (GHR) antagonist approved for clinical use. Pegvisomant is a mutated GH molecule (B2036) whi
Autor:
Amy Lai, Tet Woo Lee, John M. Chaplin, William R. Wilson, Dennis Kee, Andrew Macann, Stephen M. F. Jamieson, Tao Wang, Julia K. Harms, Francis W. Hunter, Nick McIvor
Publikováno v:
Cells
Volume 8
Issue 7
Cells, Vol 8, Iss 7, p 717 (2019)
Volume 8
Issue 7
Cells, Vol 8, Iss 7, p 717 (2019)
Tumour hypoxia is a marker of poor prognosis and failure of chemoradiotherapy in head and neck squamous cell carcinoma (HNSCC), providing a strategy for therapeutic intervention in this setting. To evaluate the utility of the hypoxia-activated prodru